RUNX1–ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development

References

• Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood 1981;58:1203–1212.
   PubMed Web of Science ®Google Scholar
• Roboz GJ. Current treatment of acute myeloid leukemia. Curr Opin Oncol 2012;24:711–719.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325–4336.
   PubMed Web of Science ®Google Scholar
• Groupe Francais de Cytogenetique Hematologique. Acute myelogenous leukemia with an 8;21 translocation. A report on 148 cases from the Groupe Francais de Cytogenetique Hematologique. Cancer Genet Cytogenet 1990;44:169–179.
   PubMed Web of Science ®Google Scholar
• Nucifora G, Rowley JD. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 1995;86:1–14.
   PubMed Web of Science ®Google Scholar
• Langabeer SE, Walker H, Rogers JR, et al. Incidence of AML1/ ETO fusion transcripts in patients entered into the MRC AML trials. MRC Adult Leukaemia Working Party. Br J Haematol 1997;99: 925–928.
   PubMed Web of Science ®Google Scholar
• Rowe D, Cotterill SJ, Ross FM, et al. Cytogenetically cryptic AML1-ETO and CBF beta-MYH11 gene rearrangements:incidence in 412 cases of acute myeloid leukaemia. Br J Haematol 2000;111:1051–1056.
   PubMed Web of Science ®Google Scholar
• Rege K, Swansbury GJ, Atra AA, et al. Disease features in acute myeloid leukemia with t(8;21)(q22;q22). Influence of age, secondary karyotype abnormalities, CD19 status, and extramedullary leukemia on survival. Leuk Lymphoma 2000;40:67–77.
   PubMed Web of Science ®Google Scholar
• Yan M, Kanbe E, Peterson LF, et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med 2006;12:945–949.
   PubMed Web of Science ®Google Scholar
• Kozu T, Fukuyama T, Yamami T, et al. MYND-less splice variants of AML1-MTG8 (RUNX1-CBFA2T1) are expressed in leukemia with t(8;21). Genes Chromosomes Cancer 2005;43:45–53.
   PubMed Web of Science ®Google Scholar
• Mulloy JC, Cammenga J, Berguido FJ, et al. Maintaining the self-renewal and differentiation potential of human CD34 + hematopoietic cells using a single genetic element. Blood 2003;102:4369–4376.
   PubMed Web of Science ®Google Scholar
• Peterson LF, Boyapati A, Ahn EY, et al. Acute myeloid leukemia with the 8q22;21q22 translocation:secondary mutational events and alternative t(8;21) transcripts. Blood 2007;110:799–805.
   PubMed Web of Science ®Google Scholar
• Muller AM, Duque J, Shizuru JA, et al. Complementing mutations in core binding factor leukemias:from mouse models to clinical applications. Oncogene 2008;27:5759–5773.
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen W, Gaudet J, et al. Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity. Cancer Cell 2007;11:483–497.
   PubMed Web of Science ®Google Scholar
• Dekelver RC, Yan M, Ahn EY, et al. Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential. Blood 2013;121:3714–3717.
   PubMed Web of Science ®Google Scholar
• Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957;147:258–267.
   PubMed Web of Science ®Google Scholar
• Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008;8:559–568.
   PubMed Web of Science ®Google Scholar
• Muller U, Steinhoff U, Reis LF, et al. Functional role of type I and type II interferons in antiviral defense. Science 1994;264:1918–1921.
   PubMed Web of Science ®Google Scholar
• O’Connell RM, Saha SK, Vaidya SA, et al. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J Exp Med 2004;200:437–445.
   PubMed Web of Science ®Google Scholar
• Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4:69–77.
   PubMed Web of Science ®Google Scholar
• Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4:63–68.
   PubMed Web of Science ®Google Scholar
• de Weerd NA, Nguyen T. The interferons and their receptors—distribution and regulation. Immunol Cell Biol 2012;90:483–491.
   PubMed Web of Science ®Google Scholar
• Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005;5:375–386.
   PubMed Web of Science ®Google Scholar
• Ank N, Iversen MB, Bartholdy C, et al. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 2008;180:2474–2485.
   PubMed Web of Science ®Google Scholar
• Kujawski LA, Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev 2007;18:459–471.
   PubMed Web of Science ®Google Scholar
• Damasio EE, Clavio M, Masoudi B, et al. Alpha-interferon as induction and maintenance therapy in hairy cell leukemia: a long-term follow-up analysis. Eur J Haematol 2000;64:47–52.
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008;22:1990–1998.
   PubMed Web of Science ®Google Scholar
• Anguille S, Lion E, Willemen Y, et al. Interferon-alpha in acute myeloid leukemia: an old drug revisited. Leukemia 2011;25:739–748.
   PubMed Web of Science ®Google Scholar
• Burel SA, Harakawa N, Zhou L, et al. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol 2001;21:5577–5590.
   PubMed Web of Science ®Google Scholar
• Shia WJ, Okumura AJ, Yan M, et al. PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential. Blood 2012;119:4953–4962.
   PubMed Web of Science ®Google Scholar
• Peterson LF, Wang Y, Lo MC et al. The multi-functional cellular adhesion molecule CD44 is regulated by the 8;21 chromosomal translocation. Leukemia 2007;21:2010–2019.
   Google Scholar
• Takaoka A, Yanai H. Interferon signalling network in innate defence. Cell Microbiol 2006;8:907–922.
   PubMed Web of Science ®Google Scholar
• Der SD, Zhou A, Williams BR, et al. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 1998;95:15623–15628.
   PubMed Web of Science ®Google Scholar
• Ahn EY, Yan M, Malakhova OA, et al. Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis. Proc Natl Acad Sci USA 2008;105:17103–17108.
   PubMed Web of Science ®Google Scholar
• Kim T, Kim TY, Song YH et al. Activation of interferon regulatory factor 3 in response to DNA-damaging agents. J Biol Chem 1999;274:30686–30689.
   PubMedGoogle Scholar
• Tamura T, Ishihara M, Lamphier MS, et al. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 1995;376:596–599.
   PubMed Web of Science ®Google Scholar
• Alcalay M, Meani N, Gelmetti V, et al. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest 2003;112:1751–1761.
   PubMed Web of Science ®Google Scholar
• Honda K, Yanai H, Takaoka A, et al. Regulation of the type I IFN induction: a current view. Int Immunol 2005;17:1367–1378.
   PubMed Web of Science ®Google Scholar
• Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004;350:1617–1628.
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Bannink M, Van Gool AR, et al. Side effects of interferon-alpha therapy. Pharm World Sci 2005;27:423–431.
   PubMed Web of Science ®Google Scholar
• Arnaud P[The interferons: pharmacology, mechanism of action, tolerance and side effects]. Rev Med Interne 2002;23(Suppl. 4):449s–458s.
   PubMed Web of Science ®Google Scholar
• Benjamin R, Khwaja A, Singh N, et al. Continuous delivery of human type I interferons (alpha/beta) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model. Blood 2007;109:1244–1247.
   PubMed Web of Science ®Google Scholar
• Osborn BL, Olsen HS, Nardelli B, et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin- interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002;303:540–548.
   PubMed Web of Science ®Google Scholar
• Dummer R, Mangana J. Long-term pegylated interferon-alpha and its potential in the treatment of melanoma. Biologics 2009;3: 169–182.
   PubMedGoogle Scholar